XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
ASSETS    
Cash and cash equivalents $ 20,217 $ 16,209
Marketable securities 5,616 15,036
Accounts receivable 750 900
Prepaid and other current assets 2,034 2,433
Total current assets 28,617 34,578
Property and equipment, net 74 72
Acquired license - intangible, net 174 192
Other assets 116 160
Total assets 28,981 35,002
Liabilities    
Accounts payable 602 1,284
Accrued liabilities 3,205 4,329
Total current liabilities 3,807 5,613
Other long-term liabilities 72 72
Total liabilities 3,879 5,685
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,620,900 and 8,409,582 shares at March 31, 2025 and December 31, 2024, respectively; and outstanding, 8,620,162 and 8,408,844 shares at March 31, 2025 and December 31, 2024, respectively 9 8
Additional paid-in capital 578,923 578,418
Treasury stock, at cost; 738 shares at March 31, 2025 and December 31, 2024 (708) (708)
Accumulated deficit (552,790) (548,066)
Accumulated other comprehensive loss (78) (81)
Total Lisata Therapeutics, Inc. stockholders' equity 25,356 29,571
Non-controlling interests (254) (254)
Total equity 25,102 29,317
Total liabilities, non-controlling interests and stockholders' equity $ 28,981 $ 35,002